Oral Teriflunomide study shows lasting efficacy and safety
Oral Teriflunomide study shows lasting efficacy and safety
The investigational oral drug teriflunomide (Aubagio) seems to have maintained its effectiveness during up to nine years of follow-up in clinical trial patients with the relapsing form of multiple sclerosis, and no late safety problems have been noticed, researchers said here.
The findings came from open-label extensions of phase II and III studies with teriflunomide, which is now under FDA review as a treatment for relapsing-remitting MS. The results were presented in a series of posters at the joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS).... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/2933
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 2062 Views
-
Last post by NHE
-
- 0 Replies
- 1342 Views
-
Last post by frodo
-
- 0 Replies
- 987 Views
-
Last post by frodo
-
- 0 Replies
- 10052 Views
-
Last post by NHE
-
- 0 Replies
- 1697 Views
-
Last post by Tif
-
- 1 Replies
- 1109 Views
-
Last post by Petr75
-
- 0 Replies
- 1814 Views
-
Last post by DIM
-
- 0 Replies
- 1947 Views
-
Last post by DIM
-
- 0 Replies
- 1580 Views
-
Last post by frodo